Presentation is loading. Please wait.

Presentation is loading. Please wait.

Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),

Published byEmel Görgülü Modified over 5 years ago

Similar presentations

Presentation on theme: "Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),"— Presentation transcript:

1 Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434), CRP (p: 0,0084; r: -0,4726), DAS28-ESR (0,0318; r: -0,3927), CDAI (p: 0,0076; r: -0,4936) and HAQ (FPR2: p: 0,05; r. -0,4438; BLT1: p: 0,0138; r: -0,5169). Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434), CRP (p: 0,0084; r: -0,4726), DAS28-ESR (0,0318; r: -0,3927), CDAI (p: 0,0076; r: -0,4936) and HAQ (FPR2: p: 0,05; r. -0,4438; BLT1: p: 0,0138; r: -0,5169). S. Perniola et al. Ann Rheum Dis 2018;77:1259 ©2018 by BMJ Publishing Group Ltd and European League Against Rheumatism

Download ppt "Statistically significant correlation between the expression of FRP2 or BLT1 in monocytes and different parameters such as ESR (p: 0,0166; r: -0,434),"

Similar presentations

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71:700-706 doi:10.1136/annrheumdis-2011-200358.

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),

 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),
The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
(A) Lequesne index and quadriceps strength of patients with knee OA

(A) Lequesne index and quadriceps strength of patients with knee OA
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
The parameters in the Reference Group model fit by EPP

The parameters in the Reference Group model fit by EPP
DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.
Changes in clinical outcome measures over 24 months on a continuous scale in the whole SWEFOT trial population with available baseline BMI categories.

Changes in clinical outcome measures over 24 months on a continuous scale in the whole SWEFOT trial population with available baseline BMI categories.

Similar presentations

Ads by Google